Goldman Sachs Initiates Coverage On MBX Biosciences with Sell Rating, Announces Price Target of $18

Benzinga · 2d ago
Goldman Sachs analyst Corinne Johnson initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Sell rating and announces Price Target of $18.